Antiarrhythmics (disopyramide, pro-cainamide, quinidine), pimozide, thyroid drugs: May increase risk of cardiac arrhythmias and con-duction defects. Monitor child closely.
Atropine, other anticholinergics (such as anti-histamines, antiparkinsonians, meperidine, phe-nothiazines): Oversedation, paralytic ileus, visu-al changes, and severe constipation. Use cau-tiously.
Barbiturates: Induced desipramine metabolism and decreased therapeutic efficacy. Monitor child closely for drug effect.
Centrally acting antihypertensives (such as cloni-dine, guanabenz, guanadrel, guanethidine, meth yldopa, reserpine): Concomitant use may de-crease hypotensive effects Monitor blood pres .-sure closely.
Cimetidine, fluoxetine, fluvoxamine, paroxetine, sertraline: May increase serum desipramine lev-els. Monitor child closely.
Clonidine, ephedrine, epinephrine, norepineph-rine, phenylephrine, phenylpropanolamine: May increase blood pressure. Monitor blood pressure closely.
CNS depressants (such analgesics, barbiturates, narcotics, tranquilizers): Ad-ditive ef-fects are likely. Avoid concomitant use.
Disulfiram, ethchlorvynol: May cause delirium and lachycardia. Monitor child closely.
Haloperidol, phenothiazines: Decreased desipra-mine metabolism, decreasing therapeutic effica-cy. Monitor child for drug effects.
MAO inhibitors: May cause severe excitation, hy-perpyrexia, or seizures usually with high dosage ,. Use cautiously together.
Metrizamide: Increased risk of seizures. Monitor child closely.
Selective serotonin-reuptake inhibiting drugs: Concomitant use may cause child toxicity to tricyclic antidepressant at much lower dosages. Use together cautiously.
Warfarin: May increase PT and cause bleeding. Monitor INR.
Sun exposure: May increase risk of photosensi-tivity. Tell parents to take precautions to exposure of children to sun. |